Myeloma

**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients**

**2024 EHA | Breaking Through Multiple Myeloma Treatment Bottlenecks: Significant Advances of Equecabtagene Autoleucel in High-Risk NDMM Patients** Multiple Myeloma (MM) is a malignant plasma cell disorder and one of the most common hematologic malignancies. In China, approximately 20,000 new cases of newly diagnosed multiple myeloma (NDMM) are reported annually, with a median age at Read More

July 12th,2024 Myeloma

IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy

###IMWG Releases 2024 RRMM CAR-T Guidelines: Equecabtagene Autoleucel Becomes China’s First Included CAR-T Therapy ###EquecabtageneAutoleucel: Leading China’s CAR-T Therapy to Global Breakthroughs In the latest guidelines released by the International Myeloma Working Group (IMWG) in 2024, Equecabtagene Autoleucel, a CAR-T therapy independently developed in China, has been officially included. This marks the first and only Read More

July 8th,2024 Myeloma

#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma

#EBMT / The Success Story of Equecabtagene Autoleucel: The World’s First Fully Human CAR-T for Multiple Myeloma In recent years, CAR-T cell therapy has made groundbreaking progress in the field of relapsed/refractory multiple myeloma (RRMM), offering hope to patients struggling with limited treatment options. Recent data shows that Equecabtagene Autoleucel achieved an impressive complete response (CR) Read More

July 5th,2024 CAR-T , Myeloma

The Journey of an Indian Cancer Patient Seeking Treatment in China: Gratitude to Be Brought Back to India

**The Journey of an Indian Cancer Patient Seeking Treatment in China: Gratitude to Be Brought Back to India** “Before coming to China for treatment, I was filled with worries. My condition was not optimistic, and I was afraid I might never see my family again… But after arriving here, everyone I met was so warm Read More

June 20th,2024 Myeloma , patient story

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient Subtitle: Fighting for Love! A story of miraculous rebirth after all treatment options failed for a late-stage multiple myeloma patient in Thailand, who underwent CAR-T therapy in China. Preface: When all treatment options had been exhausted, cancer progressed Read More

June 14th,2024 patient story , Myeloma

Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients

Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients: What other treatment options are available for patients with relapsed Multiple Myeloma? How effective is the new drug treatment for the first relapse of Multiple Myeloma? What treatment options are available for initial relapse of multiple myeloma? What are the treatment goals for Relapsed/Refractory Multiple Myeloma Read More

June 13th,2024 Myeloma

Ключевые этапы прецизионного лечения: подробный обзор инфузии CAR-T у российского пациента в шанхайской больнице Jiahui

**Заголовок: Ключевые этапы прецизионного лечения: подробный обзор инфузии CAR-T у российского пациента в шанхайской больнице Jiahui** Владимир Борзёнков, 68-летний пациент из Санкт-Петербурга, Россия, недавно завершил ключевой этап терапии CAR-T — реинфузию — в международной больнице Jiahui в Шанхае. Этот важный шаг включает повторное введение Т-клеток, которые были генетически модифицированы для распознавания и атаки определённых раковых Read More

June 5th,2024 Myeloma , patient story

Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai

Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai** Vladimir Borzenkov, a 68-year-old patient from St. Petersburg, Russia, recently completed the core phase of CAR-T therapy—reinfusion—at Jiahui International Hospital in Shanghai. This crucial step involves reinfusing T-cells, which have been genetically modified to recognize and Read More

June 5th,2024 Myeloma , patient story

Multiple Myeloma Therapy China, Bispecific BCMA/CD19 CAR-T Cell Therapy Opens New Era in the Treatment of Relapsed/Refractory Multiple Myeloma

Based on these data, a second-generation bispecific BC19 CAR targeting BCMA and CD19 was designed. This trial reports the preclinical results of BC19 CAR-T cells and the outcomes of R/R MM patients treated in the phase I/II trial.

April 28th,2024 Myeloma

2024 EBMT|Latest Data Disclosure on China’s Harvesting of RRMM CAR-T Cell Therapy Equecabtagene Autoleucel (CT103a): Efficacy Unaffected by Patients’ Baseline sBCMA Plasma Levels

During this EBMT meeting, Professor Qiu Lugui’s team reported the latest subgroup analysis results from the FUMANBA-1 study (Abstract No. OS10-04) on B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T (CAR-T) cell therapy for relapsed or refractory multiple myeloma (RRMM).

April 28th,2024 Myeloma

China’s Second CAR-T Cell Therapy Zevorcabtagene Autoleucel (CT053) Approved for Treatment of Multiple Myeloma

Following the global launch of the first approved TIL cell therapy, lifileucel, the second CAR-T product in China for the treatment of multiple myeloma, Zevorcabtagene Autoleucel (赛恺泽), has finally received approval from the National Medical Products Administration (NMPA) for its new drug application to treat adult patients with relapsed or refractory multiple myeloma.

April 27th,2024 Myeloma

Successful Case of CAR-T Cell Therapy Equecabtagene Autoleucel (CT103A) Treatment in China

In August 2023, the Department of Hematology at Nanfang Hospital, Southern Medical University, admitted a case of MM. The patient had relapsed after multiple lines of prior treatment and progressed to refractory MM with extramedullary disease.

April 27th,2024 Myeloma

Menu

Recent Posts